Aclasta, Veclade get CHMP nods

The European Medicines Agency's drug-review committee got busy today issuing recommendations--and rejections--for a laundry list of new meds and new indications for old ones. Here are the highlights.

  • Novartis' bone drug Aclasta got the nod for treating men at increased risk of fracture, including those with a recent low-trauma hip fracture. It's currently approved only for use in post-menopausal women and for treatment of Paget's disease.
  • Johnson & Johnson's blood cancer med Velcade got a thumbs-up for a new indication: use in combination with melphalan and prednisone in previously untreated multiple myeloma patients who aren't eligible for high-dose chemo. Velcade is already approved as monotherapy for patients who've tried at least one other treatment.
  • Bayer's anticlotting medicine Xarelto--one of its leading drug hopefuls--got the committee's blessing for preventing clots after surgery.
  • Sanofi-Aventis' attempt to broaden use of its cancer meds Taxotere and Docetaxel Winthrop failed to get CHMP's OK; both meds are already approved for breast cancer treatment in combination with other anticancer meds.

As you know, a committee decision isn't guaranteed to be ratified by the EMEA itself, but it generally is.

- see the roundup from CNN Money

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.